TARGETPHARMA LABORATORIES (CHANGZHOU) CO., LTD Patent applications |
Patent application number | Title | Published |
20140127736 | ANNEXIN V VARIANT AND ITS PREPARATION AND APPLICATION - The invention provides the design, preparation methods and applications of the variant of annexin V. The variant of annexin V is the protein with amino acid residue sequence in sequence 1 in the SEQUENCE LISTING, characterized in that it is the protein derived from sequence 1 by one or several amino acid residues of the sequence 1 being substituted, missing or being added and its amino acid residues have the same activity with the sequence of the sequence 1. The variant protein of the annexin V prepared form the preparation methods of the variant of the annexin V has high purity, high productivity, high labeling efficiency and stability, without effect to the biological function of the variant of the annexin V, which is applicable to industrial production and allows for further research of the variant of the annexin V. | 05-08-2014 |
20130150566 | TUMOR-TARGETED TNF-RELATED APOPTOSIS-INDUCING LIGAND'S VARIANT AND THE APPLICATION THEREOF - The invention belongs to the field of genetic engineering and biotechnology, and specifically discloses a design, preparation and pharmic application of a tumor-targeted TNF-related apoptosis-inducing ligand's variant. The tumor-targeted TNF-related apoptosis-inducing ligand's variant is generated by a fused protein which is consisted of the ligand of CD13, the connecting peptide and TNF-related apoptosis-inducing ligand's variant, and which is by the construction of coding gene of the variant according to the technology of genetic engineering and clone, soluble recombinant expression and ordinary separation and purification. The variant, produced by the method of preparation of the tumor-targeted TNF-related apoptosis-inducing ligand's variant, has favorable tumor-targeting characteristics and the significant enhancement of the anti-tumor effect. It is possible to reducing the required dosage of protein to the treatment effect, increasing the bioavailability, reducing the cost of treatment and overcome the potential toxic effects of the TNF-realated apoptosis-inducing ligand. Moreover, the preparation method of the tumor targeted TNF-related apoptosis-inducing ligand's variant of the present invention provides a method for producing the variant of soluble expression and high concern of polymer forms and a process of separation and purification thereof. | 06-13-2013 |